PATENT NO.

: 7,071,205 B2

Page 1 of 10

APPLICATION NO.: 10/684229 DATED

: July 4, 2006

INVENTOR(S)

: Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE TITLE PAGES:

In Item [56] References Cited, in U.S. PATENT DOCUMENTS: please add the following reference: --6,001,846 A 12/1999 Edwards et al. 514/285-in 6,566,358 please replace "Zhi et al." with -- Zhang et al.-in 6,566,372 please replace "West et al." with --Zhi et al.--

In Item [56] References Cited, in OTHER PUBLICATIONS: in Hamann et al., please replace "dihyrdo" with --dihydro--

At column 8, Table A, row R¹, please replace "C₁-C haloalkyl" with --C₁-C₄ haloalkyl-at column 9, Table A, row R⁹, please replace "CONR^HR¹²" with --CONR¹¹R¹²-at column 11, Table A, below row R¹⁶, please replace "R¹⁵" with --R¹⁶--

Please replace Claims 12, 13, 14, and 15 with the following Claims:

Col. 40

12. A compound of the formula:

(I)

COR"

wherein:

R¹ is selected from the group of hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ heteroalkyl, CO₂R¹¹, SO₂R¹¹, and CONR¹¹R¹²;

 R^2 and R^3 each independently is selected from the group of hydrogen, C_1 – C_6 alkyl, and C₁-C₆ haloalkyl; or

R² and R³ taken together form a cycloalkyl ring of from three to twelve carbons;

R⁴ through R⁷ each independently is selected from the group of hydrogen, F, C1, Br, CN, OR¹¹, C₁-C₄ alkyl, C₁-C₄ haloalkyl, and C₁-C₄ heteroalkyl, or

R⁵ and R⁷ taken together form a bond; or

R⁶ and R⁷ taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

Note

PATENT NO.

: 7,071,205 B2

Page 2 of 10

APPLICATION NO.: 10/684229 **DATED**

: July 4, 2006

INVENTOR(S)

: Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

 R^8 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, NO₂, CN, OR¹¹, NR¹¹R¹², SR¹¹, COR¹¹, CO₂R¹¹, CONR¹¹R¹², C₁-C₈ alkyl, C₁-C₈ heteroalkyl, C₁-C₈ haloalkyl, allyl, C₂-C₈ alkenyl and C₂-C₈ alkynyl;

R¹¹ and R¹² each is independently selected from the group of hydrogen, C₁-C₄ alkyl, C₁-C₄ heteroalkyl, and C₁-C₄ haloalkyl;

R¹³ is hydrogen;

R¹⁴ and R¹⁶ taken together form a bond or "-O-" bridge; R¹⁵, R¹⁷, R¹⁸, R¹⁹, R²⁰ each independently is selected from the group of hydrogen, F, C1, C₁-C₄ alkyl, and C₁-C₄ haloalkyl;

R²¹ is hydrogen; and n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

Col. 41

13. A compound of the formula:

(I)

PATENT NO.

: 7,071,205 B2

Page 3 of 10

APPLICATION NO. : 10/684229

DATED

: July 4, 2006

INVENTOR(S)

: Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

wherein:

R¹ is selected from the group of hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ heteroalkyl, COR¹¹, CO₂R¹¹, SO₂R¹¹, and CONR¹¹R¹²;

R² and R³ each independently is selected from the group of hydrogen, C₁-C₆ alkyl, and C₁-C₆ haloalkyl; or

R² and R³ taken together form a cycloalkyl ring of from three to twelve carbons;

R⁴ through R⁷ each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR¹¹, C₁-C₄ alkyl, C₁-C₄ haloalkyl, and C₁-C₄ heteroalkyl; or

R⁵ and R⁷ taken together form a bond; or

R⁶ and R⁷ taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R⁸ through R¹⁰ each independently is selected from the group of hydrogen, F, Cl, Br, I, NO₂, CN, OR¹¹, NR¹¹R¹², SR¹¹, COR¹¹, CO₂R¹¹, CONR¹¹R¹², C₁-C₈ alkyl, C₁-C₈ heteroalkyl, C1-C8 haloalkyl, allyl, C2-C8 alkenyl and C2-C8 alkynyl;

R¹¹ and R¹² each is independently selected from the group of hydrogen, C₁-C₄ alkyl, $C_1 - C_4$ heteroalkyl, and $C_1 - C_4$ haloalkyl:

R¹³ is hydrogen;

R¹⁴, R¹⁵, R¹⁸, R¹⁹, R²⁰ each independently is selected from the group of hydrogen, F, Cl, C_1 – C_4 alkyl, and C_1 – C_4 haloalkyl;

 R^{16} and R^{17} taken together are selected from the group of methylidene, mono-substituted methylidene, and di-substituted methylidene:

R²¹ is hydrogen; or

R²¹ and R²⁰ taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

PATENT NO.

: 7,071,205 B2

Page 4 of 10

APPLICATION NO. : 10/684229 DATED

: July 4, 2006

INVENTOR(S) : Lin Zhi et al.

> It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 42

14. A compound of the formula:

(I)

wherein:

 R^{1} is selected from the group of hydrogen, C_{1} – C_{4} alkyl, C_{1} – C_{4} haloalkyl, C_{1} – C_{4} heteroalkyl, COR^{11} , $CO_{2}R^{11}$, $SO_{2}R^{11}$, and $CONR^{11}R^{12}$;

R² and R³ each independently is selected from the group of hydrogen, C₁-C₆ alkyl, and C₁-C₆ haloalkyl; or

R² and R³ taken together form a cycloalkyl ring of from three to twelve carbons;

R4 through R7 each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR¹¹, C₁-C₄ alkyl, C₁-C₄ haloalkyl, and C₁-C₄ heteroalkyl; or

R⁵ and R⁷ taken together form a bond; or

R⁶ and R⁷ taken together are selected from the group of methylidene, mono-substituted methylidene, di-substituted methylidene and carbonyl;

R⁸ through R¹⁰ each independently is selected from the group of hydrogen, F, Cl, Br, I, NO₂, CN, OR¹¹, NR¹¹R¹², SR¹¹, COR¹¹, CO₂R¹¹, CONR¹¹R¹², C₁-C₈ alkyl, C₁-C₈ heteroalkyl, C_1 – C_8 haloalkyl, allyl, C_2 – C_8 alkenyl and C_2 – C_8 alkynyl,

PATENT NO.

: 7.071205 B2

Page 5 of 10

APPLICATION NO.: 10/684229 DATED

: July 4, 2006

INVENTOR(S)

: Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R¹¹ and R¹² each is independently selected from the group of hydrogen, C₁-C₄ alkyl, C₁- C_4 heteroalkyl, and C_1 – C_4 haloalkyl:

R¹³ is hydrogen;

 R^{14} , R^{15} , R^{17} , R^{20} each independently is selected from the group of hydrogen, F, Cl, C₁- C_4 alkyl, and C_1 – C_4 haloalkyl;

R¹⁶ and R¹⁸ taken together form a bond when n is 1; R¹⁶ and R¹⁹ taken together form a bond when n is 0;

R²¹ is hydrogen; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

Col. 42-45

15. A Compound selected from the group of:

(±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5Hchromeno[3,4-f]quinoline (compound 24):

(±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5Hchromeno[3,4-f]quinoline (compound 25);

(+)-(51,1'l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5Hchromeno[3,4-f]quinoline (compound 27);

(-)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5Hchromeno[3,4-f]quinoline (compound 28);

(±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5Hchromeno[3,4-f]quinoline (compound 29);

PATENT NO. : 7,071,205 B2 APPLICATION NO. : 10/684229

,071,205 B2 Page 6 of 10 0/684229

DATED : July 4, 2006 INVENTOR(S) : Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 30);
- (+)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-cbromeno[3,4-fjquinoline (compound 32);
- (-)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-fJquinoline (compound 33);
- (±)-(51,1'1)-5-3-methy1-2-cyclohexeny1)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 34);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 35);
- (+)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 37);
- (-)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 38);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 39);
- (\pm)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 41);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 42);
- (±)-(51,1'1)-5-(3-methy1-2-cyclopenteny1)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 44);
- (±)-(51,1'u)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethy-5H-chromeno[3,4-f]quinoline (compound 45);

PATENT NO. : 7,071,205 B2

71,205 B2 Page 7 of 10/684229

APPLICATION NO.: 10/684229
DATED: July 4, 2006
INVENTOR(S): Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'1)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 47);
- (±)-(51,1'u)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 48);
- (±)-(51,1'1)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 50);
- (±)-(51,1'u)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 51);
- (±)-5-(3-methyl-3-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 52);
- (±)-5-(2-cyclopenta-1,3-dienyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 53);
- (±)-(51,1'1)-5-(3-ethy1-2-cyclohexeny1)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 55);
- (±)-(51,1'u)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 56);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 58);
- (±)-(51,1'u)-5-(3-methy1-2-cyclohexeny1)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 59);
- (±)-(51,1'1)-5-(3-ethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 61):
- (±)-(51,1'1)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 62);

PATENT NO. : 7,071,205 B2

,071,205 B2 Page 8 of 10 0/684229

APPLICATION NO.: 10/684229
DATED: July 4, 2006
INVENTOR(S): Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'1)-5-(3-methyl-3-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 63);
- (±)-(51,1'1)-5-(3-methyl-2-cyclobexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 64);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 65);
- (±)-(51,1'1)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 67);
- (±)-(51,1'u)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 68);
- (±)-5-(1-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethy1-5H-chromeno[3,4-f]quinoline (compound 69);
- (±)-(51,1'1)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 71);
- (+)-(51,1'1)-5-(2,3-dimethyl-2-eyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 73);
- (-)-(51,1'1)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 74);
- (±)-(51,1'1)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 75);
- (±)-(51,1'u)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 76);
- (±)-(51,1'1)-5-(2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylidene-5H-chromeno[3,4-f]quinoline (compound 77);

PATENT NO.

: 7,071,205 B2

Page 9 of 10

APPLICATION NO.: 10/684229 DATED

: July 4, 2006

INVENTOR(S)

: Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (\pm) -(51,1'l)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5Hchromeno[3,4-f]quinoline (compound 79):
- (±)-(51,1'u)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5Hchromeno[3,4-f]quinoline (compound 80):
- (±)-(51,1'1)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4flquinoline (compound 81):
- (\pm) -(51,1'u)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-1,2H-chromeno[3,4H-ch f]quinoline (compound 82);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-1,2,2,4-tetramethyl-5Hchromeno[3,4-f]quinoline (compound 83);
- (±)-5-(2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]difluoro quinoline (compound 84);
- (±)-(51,1'1)-5-(2,3-dimethyl-2-cyclohexenyl)-7,9-45-4-4-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 85); cyclohexyl
- (±)-5-(3-methylidene-autorativi)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5Hchromeno[3,4-f]quinoline (compound 87);
- (±)-(51,1'u)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5Hchromeno[3,4-f]quinoline (compound 88);
- (±)-(51,1'1)-5-(2-cyclohepteny1)-7,9-difluoro-1,2-dihydro-2,2,4-trimethy1-5Hchromeno[3,4-f]quinoline (Compound 89);
- (±)-(51,1'1)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5Hchromeno[3,4-f]quinoline (Compound 91);
- (±)-(51,1'u)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5Hchromeno[3,4-f]quinoline (Compound 92);

Note

PATENT NO.

: 7,071,205 B2

Page 10 of 10

APPLICATION NO.: 10/684229 : July 4, 2006

DATED INVENTOR(S)

: Lin Zhi et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-(51,1'1)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 94);

(±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4methylene-5H-chromeno[3,4-f]quinolin-3-ol (Compound 95);

(±)-(51,1'1)-5-(2,3-epoxy-2,3-dimethylcyclopentyl)-7,9-difluoro-1,2-dihydro-2,2,4trimethyl-5H-chromeno[3,4-f]quinoline (Compound 96);

(±)-(51,1'u)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4trimethy1-5H-chromeno[3,4-f]quinoline (Compound 97); and

(±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5H-chromeno[3,4-f]quinolin-4-one (Compound 98).

This certificate supersedes certificate of correction.
issued November 28, 2006.

istandale Bulla badgitt The only selected Day of November 20016

eathdracadur Diversed of the Deniet States Proportion It of States of Office

Note